OTC Pharmaceuticals in Japan

Introduction

OTC Pharmaceuticals in Japan industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Japan otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

• The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2010 annual average exchange rates.
• The Japanese OTC pharmaceuticals market generated total revenues of $13 billion in 2010, representing a compound annual growth rate (CAGR) of 1.7% for the period spanning 2006-2010.
• Traditional medicines sales proved the most lucrative for the Japanese OTC pharmaceuticals market in 2010, generating total revenues of $4.3 billion, equivalent to 33% of the market's overall value.
• The performance of the market is forecast to decelerate, with an anticipated CAGR of 1.5% for the five-year period 2010-2015, which is expected to lead the market to a value of $14 billion by the end of 2015.

Features

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Japan
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Japan
• Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Japan otc pharmaceuticals market with five year forecasts by both value and volume
• Macroeconomic indicators provide insight into general trends within the Japan economy

Key Questions Answered

• What was the size of the Japan otc pharmaceuticals market by value in 2010?
• What will be the size of the Japan otc pharmaceuticals market in 2015?
• What factors are affecting the strength of competition in the Japan otc pharmaceuticals market?
• How has the market performed over the last five years?
• Who are the top competitiors in Japan's otc pharmaceuticals market?

Contents

EXECUTIVE SUMMARY

MARKET OVERVIEW

Market definition
Market analysis

MARKET DATA

Market value

MARKET SEGMENTATION

Category segmentation
Geography segmentation
Market share
Market distribution

MARKET OUTLOOK

Market value forecast

FIVE FORCES ANALYSIS

Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry

LEADING COMPANIES

Johnson & Johnson
Kracie Holdings, Ltd.
Novartis AG

MACROECONOMIC INDICATORS

Country Data

APPENDIX

Methodology
Industry associations
Related MarketLine research

LIST OF TABLES

Table 1: Japan OTC pharmaceuticals market value: $ million, 2006–10
Table 2: Japan OTC pharmaceuticals market category segmentation : % share, by value, 2006 - 2010
Table 3: Japan OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010
Table 4: Japan OTC pharmaceuticals market geography segmentation, by value, 2010
Table 5: Japan OTC pharmaceuticals market share: % share, by value, 2010
Table 6: Japan OTC pharmaceuticals market distribution: % share, by value, 2010
Table 7: Japan OTC pharmaceuticals market value forecast: $ million, 2010–15
Table 8: Johnson & Johnson: key facts
Table 9: Johnson & Johnson: key financials ($)
Table 10: Johnson & Johnson: key financial ratios
Table 11: Kracie Holdings, Ltd.: key facts
Table 12: Novartis AG: key facts
Table 13: Novartis AG: key financials ($)
Table 14: Novartis AG: key financial ratios
Table 15: Japan size of population (million), 2006–10
Table 16: Japan gdp (constant 2000 prices, $ billion), 2006–10
Table 17: Japan gdp (current prices, $ billion), 2006–10
Table 18: Japan inflation, 2006–10
Table 19: Japan consumer price index (absolute), 2006–10
Table 20: Japan exchange rate, 2006–10

LIST OF FIGURES

Figure 1: Japan OTC pharmaceuticals market value: $ million, 2006–10
Figure 2: Japan OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010
Figure 3: Japan OTC pharmaceuticals market geography segmentation : % share, by value, 2010
Figure 4: Japan OTC pharmaceuticals market share: % share, by value, 2010
Figure 5: Japan OTC pharmaceuticals market distribution: % share, by value, 2010
Figure 6: Japan OTC pharmaceuticals market value forecast: $ million, 2010–15
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Japan, 2010
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Japan, 2010
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Japan, 2010
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Japan, 2010
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Japan, 2010
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Japan, 2010
Figure 13: Johnson & Johnson: revenues & profitability
Figure 14: Johnson & Johnson: assets & liabilities
Figure 15: Novartis AG: revenues & profitability
Figure 16: Novartis AG: assets & liabilities
Skip to top